119 related articles for article (PubMed ID: 38764581)
1. Dynamic changes in tumor profiling reveal intra- and inter-tumoral heterogeneity focused on an uncharacterized HER2 mutation: a case report of a young breast cancer patient.
Schaffrin-Nabe D; Josten-Nabe A; Tannapfel A; Uhl W; Garmer M; Kurzrock R; Crook T; Limaye S; Schuster S; Patil D; Schaffrin M; Mokbel K; Voigtmann R
Front Oncol; 2024; 14():1395618. PubMed ID: 38764581
[TBL] [Abstract][Full Text] [Related]
2. Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer.
Kong SL; Liu X; Tan SJ; Tai JA; Phua LY; Poh HM; Yeo T; Chua YW; Haw YX; Ling WH; Ng RCH; Tan TJ; Loh KWJ; Tan DS; Ng QS; Ang MK; Toh CK; Lee YF; Lim CT; Lim TKH; Hillmer AM; Yap YS; Lim WT
Front Oncol; 2021; 11():698551. PubMed ID: 34336686
[TBL] [Abstract][Full Text] [Related]
3. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
4. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.
Paoletti C; Cani AK; Larios JM; Hovelson DH; Aung K; Darga EP; Cannell EM; Baratta PJ; Liu CJ; Chu D; Yazdani M; Blevins AR; Sero V; Tokudome N; Thomas DG; Gersch C; Schott AF; Wu YM; Lonigro R; Robinson DR; Chinnaiyan AM; Bischoff FZ; Johnson MD; Park BH; Hayes DF; Rae JM; Tomlins SA
Cancer Res; 2018 Feb; 78(4):1110-1122. PubMed ID: 29233927
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
7. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Naqvi MF; Vo HH; Vining D; Tsimberidou AM
Ther Adv Med Oncol; 2021; 13():17588359211001538. PubMed ID: 33995588
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine in breast cancer: pharmacogenomics approaches.
Jeibouei S; Akbari ME; Kalbasi A; Aref AR; Ajoudanian M; Rezvani A; Zali H
Pharmgenomics Pers Med; 2019; 12():59-73. PubMed ID: 31213877
[No Abstract] [Full Text] [Related]
9. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
10. The potential for liquid biopsies in the precision medical treatment of breast cancer.
Forte VA; Barrak DK; Elhodaky M; Tung L; Snow A; Lang JE
Cancer Biol Med; 2016 Mar; 13(1):19-40. PubMed ID: 27144060
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Bardia A; Iafrate JA; Sundaresan T; Younger J; Nardi V
Oncologist; 2016 Sep; 21(9):1035-40. PubMed ID: 27551012
[TBL] [Abstract][Full Text] [Related]
12. Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA.
Banys-Paluchowski M; Fehm TN; Grimm-Glang D; Rody A; Krawczyk N
Oncol Res Treat; 2022; 45(1-2):4-11. PubMed ID: 34718243
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.
De Luca F; Rotunno G; Salvianti F; Galardi F; Pestrin M; Gabellini S; Simi L; Mancini I; Vannucchi AM; Pazzagli M; Di Leo A; Pinzani P
Oncotarget; 2016 May; 7(18):26107-19. PubMed ID: 27034166
[TBL] [Abstract][Full Text] [Related]
15. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.
Iams WT; Mackay M; Ben-Shachar R; Drews J; Manghnani K; Hockenberry AJ; Cristofanilli M; Nimeiri H; Guinney J; Benson AB
JAMA Netw Open; 2024 Jan; 7(1):e2351700. PubMed ID: 38252441
[TBL] [Abstract][Full Text] [Related]
17. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer.
Gao J; Wang H; Zang W; Li B; Rao G; Li L; Yu Y; Li Z; Dong B; Lu Z; Jiang Z; Shen L
Cancer Sci; 2017 Sep; 108(9):1881-1887. PubMed ID: 28677165
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.
Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z
Front Oncol; 2022; 12():830816. PubMed ID: 35280779
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
